Literature DB >> 8627026

Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.

I Takahashi1, M Marinaro, H Kiyono, R J Jackson, I Nakagawa, K Fujihashi, S Hamada, J D Clements, K L Bost, J R McGhee.   

Abstract

Escherichia coli labile toxin (LT) was assessed as mucosal immunogen and as adjuvant for tetanus toxoid (TT) in mice. After oral administration of LT, C57BL/6 (H-2b) and BALB/c(H-2d) mice were high mucosal and serum antibody responders, while C3H/HeN (H-2k) mice were low responders. High responders exhibited mainly serum IgG (including IgG1, IgG2a, and IgG2b), as well as IgM and IgA, while mucosal responses were IgA. Analysis of LT-B-specific CD4+ T helper (Th) cells from Peyer's patches (PP) or from spleen revealed a mixed Th1 (interferon-gamma) and Th2 (interleukin-4 and -5) cell pattern. Oral LT given with TT induced TT-specific response patterns identical to LT-B. Analysis of mRNA from TT-specific PP CD4+ Th cells also revealed a mixed Th1- and Th2- type response. Thus, antibody response profiles induced by LT are regulated by both CD4+ Th1 and Th2 cell types.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627026     DOI: 10.1093/infdis/173.3.627

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

Review 1.  Immunotherapy for food allergies. Past, present, future.

Authors:  S B Lehrer; L G Wild; K L Bost; R U Sorensen
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Interleukin 12 and innate molecules for enhanced mucosal immunity.

Authors:  P N Boyaka; J W Lillard; J McGhee
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

3.  Enhanced mucosal and systemic immune responses to intestinal reovirus infection in beta2-microglobulin-deficient mice.

Authors:  A S Major; C F Cuff
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  The identification of plant lectins with mucosal adjuvant activity.

Authors:  E C Lavelle; G Grant; A Pusztai; U Pfüller; D T O'Hagan
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

5.  Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs.

Authors:  Valeria Alcon; Maria Baca-Estrada; Marco Vega-Lopez; Philip Willson; Lorne A Babiuk; Praveen Kumar; Rolf Hecker; Marianna Foldvari
Journal:  AAPS J       Date:  2005-10-14       Impact factor: 4.009

6.  Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.

Authors:  Haibo Li; Jinyong Zhang; Yafei He; Bin Li; Li Chen; Weiwei Huang; Quanming Zou; Chao Wu
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

Review 7.  Oral tolerance.

Authors:  W Strober; B Kelsall; T Marth
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

8.  Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.

Authors:  G Douce; M Fontana; M Pizza; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

9.  Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.

Authors:  Frederik W van Ginkel; Raymond J Jackson; Naoto Yoshino; Yukari Hagiwara; Daniel J Metzger; Terry D Connell; Hong L Vu; Michael Martin; Kohtaro Fujihashi; Jerry R McGhee
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

10.  Role of T cells in the adjuvant effect of Bacillus firmus on the immune system of mice: intranasal and intratracheal immunization study with ovalbumin.

Authors:  P Mlcková; D Cechová; L Marusková; P Chalupná; O Novotná; L Prokesová
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.